IGFBP-3 has both stimulatory and inhibitory effects on cancer progression. The growth of EO771 mammary carcinoma cells as syngeneic tumors in C57BL/6 mice is reduced in Igfbp3-null (BP3KO) mice, suggesting that systemic IGFBP-3 enhances tumor progression. In this study we assessed the growth of EO771 cells expressing human IGFBP-3 in BP3KO mice. Cells expressing hIGFBP-3 showed decreased proliferation in vitro and increased levels of IGF-1 receptor (IGF1R) protein but not mRNA, consistent with sequestration of endogenous IGF by IGFBP-3. The growth rate of these cells was restored by exposure to IGF-1 or analogues with reduced affinity for IGFBP-3 (long Arg 3 -IGF-1) or IGF1R (Leu 24 -IGF-1). In EO771 cells implanted orthotopically into mice, hIGFBP-3 expression by the cells inhibited tumor establishment in BP3KO but not wild-type mice. For tumors that successfully established, final weight was not affected significantly by hIGFBP-3 expression. However, final tumor weight was inversely related to intratumoral T cell counts, and sera from BP3KO mice with tumors showed lowtiter immunoreactivity against IGFBP-3. The contrasting effects on tumor establishment and progression of IGFBP-3 expressed by mammary carcinoma cells, compared to systemic stromal and circulating IGFBP-3, highlights the complexity of growth regulation by IGFBP-3 in mammary tumors.
Introduction
Insulin-like growth factor binding protein-3 (IGFBP-3), the most abundant IGFBP in the circulation of adult mammals, binds IGF-1 and IGF-2 in the cellular environment, limiting their access to the type 1 IGF receptor (IGF1R). Studies investigating the impact of IGFBP-3 on tumor progression have shown that its effects can be either dependent or independent of its ability to bind IGFs [1] and that the role of IGFBP-3 on cancer progression is complex, with both stimulatory and inhibitory effects on growth. There is extensive evidence arising from in vitro and in vivo basic studies that IGFBP-3 exerts growth-inhibitory and proapoptotic effects through a variety of mechanisms that include activation of nuclear hormone receptors [2, 3] , TGFβ receptors [4] , and a novel receptor identified as TMEM219 [5] . Epigenetic suppression of IGFBP3 appears to contribute to the growth of some cancers including hepatocellular carcinoma [6] .
Despite these observations supporting the role of IGFBP-3 as a putative tumor suppressor, high IGFBP-3 expression in breast cancer has been associated with worse prognosis [7] [8] [9] [10] , suggesting that resistance to its growth inhibitory effects can arise. This has been observed experimentally in vitro and in vivo where the expression of the Ras oncogene ameliorates mammary epithelial cell sensitivity to IGFBP-3-induced growth inhibition [11] , and the overexpression of IGFBP-3 in a breast cancer cell line leads to cell proliferation rates switching from growth inhibition at early passage to growth stimulation at late passage [12] . Tumor growth of these IGFBP-3-overexpressing cells in vivo show potentiation of EGFR signaling with increased levels of phosphorylated EGFR [12] . This may be explained by the capacity for IGFBP-3 to stimulate sphingosine kinase expression and activity [13, 14] , leading to the transactivation of EGFR signaling which is consistent with tumor growth stimulation and worse prognosis [13, 15, 16] . Overall, these observations highlight that the influence of IGFBP-3 is highly context-dependent.
It is now recognised that the tumor microenvironment plays a major role in the progression of cancer [17] , with tumor stromal gene expression shown to be of prognostic importance [18] . Considering that IGFBP-3 is expressed across various cell types [19] [20] [21] including breast stromal tissue [22] , it is likely that IGFBP-3 in the tumor microenvironment can potentially influence tumor progression. This is supported by studies examining the effect of IGFBP-3 expression using mouse models which have shown that IGFBP-3 has effects on the tumor microenvironment that ultimately impact tumor growth. Increased intratumoral levels of IGFBP-3, induced either by adenoviral-mediated overexpression in lung, head and neck [23, 24] or through recombinant protein injection into prostate [25] tumor xenografts, were shown to result in reduced blood vessel formation and tumor growth, suggesting that high levels of IGFBP-3 in the tumor microenvironment are detrimental to tumor development.
We have recently reported that the growth of EO771 murine mammary tumor cells, with no detectable expression of IGFBP-3, was reduced in Igfbp3-null (BP3KO)* mice compared to wildtype controls, suggesting that systemic IGFBP-3, which may be circulatory or present in the tumor microenvironment, has a tumor growth-promoting influence in this model [26] . To gain a better understanding of how IGFBP-3 might influence tumor growth in an IGFBP-3-deficient microenvironment, we have examined the capacity of murine mammary tumor cells -induced to express hIGFBP-3 -for tumor growth in the BP3KO mouse model.
Materials and methods

Reagents
Recombinant human IGF-I was a gift from Genentech, South San Francisco, CA, USA. Long Arg 3 -IGF-I (LR3) and Leu 24 -IGF-1 (L24) were purchased from GroPep Bioreagents, Thebarton, South Australia. LR3 has a greatly reduced affinity for IGFBP-3 but essentially normal binding to IGF1R [27] , whereas L24 has a greatly reduced affinity for IGF1R but essentially normal binding to IGFBP-3 [28] . Rabbit antiserum R-100 against full-length human IGFBP-3 was raised in-house.
Transfection of EO771 cell line
EO771 murine mammary carcinoma cells (RRID: CVCL_GR23) were a gift from Prof. Robin Anderson, Peter MacCallum Cancer Centre, Melbourne, Australia and were maintained in RPMI 1640 medium supplemented with 5% fetal calf serum (FCS) and HEPES on tissue culture plastic. These cells are described as phenotypically basal-like and triple-negative i.e. they lack estrogen (ER) and progesterone receptors, and do not display HER2 amplification [29] . Cell line authentication was not undertaken owing to a lack of standard for short tandem repeat profiling. EO771 cells stably expressing human IGFBP-3 (EO771-BP3), and empty vector control cells (EO771-VEC), were generated by Dr Mike Zhen Lin, Kolling Institute, Sydney, Australia. The empty pcDNA4 plasmid and the pcDNA4 vector containing the IGFBP-3 cDNA sequence were transfected into wildtype EO771 cells by electroporation using Amaxa Cell Line Nucleofector Kit V (Lonza, Mount Waverley, Victoria, Australia). Transfected cells were selected by expansion in the presence of Zeocin for two passages prior to freezing down for storage. Human rather than murine IGFBP-3 was chosen for overexpression to allow its specific measurement with a primate-specific IGFBP-3 immunoassay [30] (using antiserum R-100 at 1:100,000 dilution) on a background containing the murine protein. Alignment of the human IGFBP-3 sequence (UniProt: P17936.2) with the mouse sequence (GenBank: AAH58261.1) using BLAST (NCBI, Bethesda, MD, USA) shows 80% homology between species with key interaction sites conserved.
Cell proliferation analysis
Cells were plated onto 0.2% gelatin-coated wells of 24- 
Measurement of gene expression
Total RNA from adipose tissue and tumors was extracted with TRIzol reagent and purified with Direct-zol™ RNA MiniPrep. RNA was quantitated by Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and reverse-transcribed with Maxima H Minus Reverse Transcriptase according to the manufacturer's instructions. Quantitative real-time PCR was performed in an ABI 7900HT (Applied Biosystems, Foster City, CA, USA) using Taqman probes (Igf1r, Mm00802831_m1; IGFBP3, HS00181211_M1). Transcripts for each sample were assayed in duplicate and quantitated relative to hydroxylmethylbilane synthase (HMBS, murine or human respectively).
Mouse studies
Animal studies were conducted in the Kearns Facility, Kolling Institute, Sydney, with the approval of the Royal North Shore Hospital Animal Care and Ethics Committee (ACEC protocol RESP-14-211). For tumor formation, Igfbp3 global knock-out (BP3KO) mice [26] Mice were sacrificed 21 days after cells were implanted. Tumor immunohistochemistry for CD3 was performed as previously described [26] , with heat-retrieval using a Tris-EDTA pH 9.0 buffer and antibody A0452 (RRID:AB_2335677) from Dako (North Sydney, NSW, Australia) at 1.5 μg/mL final dilution.
Detection of circulating antibodies against hIGFBP-3
Serum aliquots (10 μL) were diluted 20-fold and incubated at 4°C overnight with 8-10,000 cpm/tube of tracer ( 125 I-IGF-1 covalently crosslinked to hIGFBP-3 [30] ). To separate the bound antibodies, Protein A-agarose beads (20 μL) were added to serum-tracer mixture and incubated on ice for 30 min with frequently agitation. The beads containing bound antibodies were pelleted at 13,000×g for 5 min at 4°C and washed by aspiration of the supernatant and replacement with buffer, prior to removal of all supernatant. Bound tracer was counted on a γ-counter.
Statistical methods
Analyses were performed using Prism version 6.00 for Windows, (GraphPad Software, La Jolla, CA, USA). Significant differences were determined by Fisher's exact test, Kruskal-Wallis test, 1-way or 2-way ANOVA followed by post-hoc Tukey's test, or by t-test, as indicated. Results were considered statistically significant when p < 0.05.
Results
Growth of EO771 cells expressing hIGFBP-3 in vitro
The EO771 cell line is syngeneic with the C57BL/6 strain, on which the BP3KO mice are based. The secretion of hIGFBP-3, measured by specific RIA, into culture medium is shown in Fig. 1A . IGFBP-3 levels were below the limit of detection in control cells whereas approximately 50 ng/mL IGFBP-3 was present in medium from IGFBP-3-secreting cells after 72 h, within the range of IGFBP-3 secretion by human breast cancer cell lines [16] . Murine IGF-1 measured by specific ELISA was undetectable (i.e. < 8 pg/mL) in either EO771-VEC or EO771-BP3 conditioned media (data not shown). Examined by IncuCyte live-cell imaging, EO771-VEC cells showed a greater proliferation rate than EO771-BP3 cells (p = 0.021, repeated measures ANOVA; Fig. 1B ). Analysis of cell lysates by western blotting revealed that EO771-BP3 cells had approximately 2.5-fold greater levels of IGF1R than control cells (Fig. 1C) . However, Igf1r gene expression levels were similar between the two transfected cell types (Fig. 1D ) and when compared with the untransfected EO771 cells and the unrelated 4T1 murine mammary carcinoma cell line, indicating that the IGF1R upregulation occurred at the translational or post-translational level.
To determine if the suppressed growth of the EO771-BP3 cells relative to EO771-VEC cells is related to the ability of IGFBP-3 to compete with IGF1R for IGF binding, cells were treated with 100 ng/mL of either IGF-1 or long Arg 3 -IGF-I (LR3), an IGF-1 analogue with greatly reduced affinity for IGFBP-3. Treatment with the non-binding IGF-1 analogue or with IGF-1 had negligible effect on the growth rates of the EO771-VEC cells (p = 0.70 for area under the curve (AUC) across ligands for EO771-VEC only, 1-way ANOVA), suggesting that these cells were maximally stimulated by IGFs present in the growth medium. Since the cells did not secrete detectable mIGF-1, IGFs in the medium may be bovine IGF-1 or −2 present in the 5% FCS. In contrast, treatment with IGF-1 or LR3 increased the growth of the EO771-BP3 cells (p = 0.0008 for AUC across ligands for EO771-BP3 only, 1-way ANOVA) ( Fig. 2A) .
The reversal of the decreased growth rate in the EO771-BP3 cells by excess IGF-1 or LR3 suggested that it could be attributed to IGF binding by overexpressed hIGFBP-3. The IGF1R level in EO771-BP3 cells, which was increased relative to EO771-VEC cells (Fig. 1C) , was not significantly affected by the addition of IGF-1 or LR3 (data not shown).
Since it appeared that the reduced growth rate of EO771-BP3 cells was due to IGF binding by overexpressed IGFBP-3, an IGF-1 analogue with normal IGFBP-3 binding but an 18-fold reduced affinity for IGF1R, Leu 24 -IGF-1 (L24) [28] , was tested in the same system. As expected, the increased levels of phosphorylated IGF1R seen after 10 min exposure of EO771-VEC and EO771-BP3 cells to IGF-1 was not seen on exposure to L24 (Fig. 2B) . Treatment with 100 ng/mL IGF-1 or L24 had no effect on the overall growth rate of the EO771-VEC cells (p = 0.07 across ligands for EO771-VEC cells only, 1-way ANOVA for AUC) but increased the growth of EO771-BP3 cells (L24: 4635 ± 162 vs Control: 4157 ± 153 vs IGF1: 5010 ± 200 AUC, p = 0.006, 1-way ANOVA (Fig. 2C) ). As seen for IGF-1 and LR3 treatment, the increased IGF1R levels in the EO771-BP3 cells were not affected by exposure to L24 (data not shown). Since L24 cannot directly activate IGF-1R (Fig. 2B) , we interpret the growth-stimulatory effect of L24 in EO771-BP3 cells as indicating that excess L24 can displace endogenous IGFs from hIGFBP-3, which are then available to stimulate cell growth over 6 days. This displacement of endogenous IGFs by L24 would not be expected in the acute setting of the IGF1R activation in Fig. 2B since the L24 concentration was lower (25 vs 100 ng/mL), and the duration of exposure was much shorter (5-10 min vs 6 days).
Influence of tumor-derived IGFBP-3 on tumor growth in wildtype and BP3KO mice
The influence of tumor-derived IGFBP-3 on tumor growth was next investigated in vivo. Wildtype C57BL/6 and BP3KO mice were implanted with either EO771-VEC or EO771-BP3 cells. In tumors harvested from the mice 21 days post-implantation, IGFBP3 gene expression within the EO771-BP3 tumors was maintained at a level similar to 3 . A: Gene expression of IGFBP3 in EO771 cell cultures transfected to express hIGFBP-3 or empty vector control (n = 2 per condition) and in whole tumors derived from these cells (n = 6 per group). Mean values ± SEM. B: BP3KO mice implanted with EO771 cells expressing hIGFBP-3 were significantly less likely to form successful tumors than those implanted with vector control EO771 cells (p = 0.003, Fisher's exact test). Tumors not palpable at the time of sacrifice were considered to have failed. The fraction of successful tumors (number of tumors/number of mice) is shown above the bars, with the percentage in the green bars. C: Individual tumor weights measured 21 days post-implantation, with mean value ± SEM indicated for each group. Of tumors that formed successfully, the apparent inhibitory effect of hIGFBP-3 expression on overall tumor growth in BP3KO mice was not statistically significant.
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Experimental Cell Research 374 (2019) [38] [39] [40] [41] [42] [43] [44] [45] that in cultured cells (Fig. 3A) . As seen in Fig. 3B , EO771-BP3 cells were significantly less likely to form tumors that were palpable after 21 days in BP3KO mice (p = 0.003, Fisher's exact test) but not in WT mice (p = 0.1, Fisher's exact test), with the failure rate in BP3KO mice (67%) significantly higher than that in WT mice (16%; p = 0.007, Fisher's exact test). However, in the tumors that formed, IGFBP-3 expression did not significantly affect final tumor weight in the wildtype mice (p = 0.22 for cell expression of IGFBP-3, 2-way ANOVA), and in BP3KO mice the apparent decrease in tumor weight was not statistically significant (Fig. 3C ).
3.3. Influence of tumor-derived IGFBP-3 on the adaptive immune response
Infiltration of T cells into tumors and mammary fat pads
The unexpected difference in tumor establishment between wildtype and BP3KO mice with IGFBP-3-expressing tumor cells suggested the possible involvement of an immune response. To assess T cell infiltration into tumors and mammary fat pads, tumors were examined by IHC using the pan-T cell marker, CD3, as an increased abundance of T cells would indicate an adaptive immune response against the tumor. In the case of tumors that were not palpable and, therefore, considered not to have successfully established, the entire mammary fat pad was sectioned. These sections were first examined morphologically by hematoxylin and eosin staining for potential remaining tumor cells and then examined by IHC for CD3 + T cells. This analysis revealed the presence of clusters of CD3 + T cells as exemplified in Fig. 4A and B. The percentage of CD3 + T cells in successfully established tumors was not significantly different among groups (Fig. 4C ), but higher intratumoral T cell counts were associated with decreased tumor growth (Fig. 4D) , and fat pads in which tumors failed to establish also showed high T cell counts (data not shown), consistent with the literature reporting that T cell infiltration into tumors is negatively associated with tumor growth [31, 32] .
Antibodies against tumor-derived hIGFBP-3
The immune response, if elicited, may have been either a direct response to the perception of hIGFBP-3 as a foreign antigen, or a demonstration of the influence of IGFBP-3 within the immune system. The presence of reactive T cells can be associated with the maturation of Bcells with a consequent release of antibodies [33] . Therefore, to determine if the differences in tumor establishment observed between wildtype and BP3KO mice implanted with cells with hIGFBP-3 expression were related to the generation of an immune response directed against IGFBP-3, sera from the mice were analysed for the presence of antibodies against hIGFBP-3.
As a positive control, high-titer rabbit antiserum R-100 against fulllength hIGFBP-3 was used. Increasing amounts of R-100 at 1:100,000 dilution were incubated with a covalent complex of 125 I-IGF-1 and hIGFBP-3 [30] prior to precipitation with Protein A-agarose beads. Fig. 5A shows increasing binding of IGF-I/IGFBP-3 tracer to increasing control antiserum concentrations. Mouse sera were tested at 10 μL of a 1:20 dilution. In comparison to sera obtained from wildtype mice with either control (EO771-VEC) or IGFBP-3-expressing (EO771-BP3) tumors, sera from BP3KO mice with EO771-BP3 tumors showed the presence of low titer antibodies reactive against IGFBP-3 ( Fig. 5B ).
Binding below a B/B 0 ratio of 1 is nonspecific. This suggests that the growth of EO771-BP3 tumors in BP3KO mice is associated with a lowlevel immune response to hIGFBP-3 produced by these cells, but whether this is related to the increased tumor rejection rate in these mice is unclear.
Discussion
This study aimed to delineate the role of mammary tumor cell- derived IGFBP-3 on cell proliferation in vitro, and tumor growth in wildtype and BP3KO mice. EO771 cells expressing hIGFBP-3 showed reduced proliferation in vitro compared to control cells, similar to some other studies in which overexpressed, induced, or exogenous IGFBP-3 is associated with growth inhibition in ER-positive human breast cancer cell lines [4, 34, 35] . Induced (e.g. by TGFβ) [36] or exogenous [37] IGFBP-3 has also been shown to be inhibitory in human triple-negative breast cancer (TNBC) cells in some studies. In contrast, other studies in TNBC cell lines link endogenous cellular IGFBP-3 with increased growth rates mediated through enhanced EGFR and IGF1R signaling activated by increased activity of sphingosine kinase 1 [13] . Human TNBC cells typically show high endogenous IGFBP-3 expression [16] , in contrast to human ER-positive cell lines which typically produce low or negligible IGFBP-3. Although the murine mammary carcinoma line EO771, syngeneic with C57BL/6 mice, is described as basal-like and triple-negative [29] , it expresses no detectable mIGFBP-3. We therefore expressed IGFBP-3 in these cells by stable transfection, using hIGFBP-3 to allow its specific detection in the presence of the murine protein. This resulted in a reduced proliferation rate which could be restored to a similar level as control, vector-transfected cells by exposure to excess IGF-1 or LR3-IGF-1. The growth of control cells (in medium containing 5% FCS) was not stimulated by added IGF-1 or LR3. This contrasts with the reported stimulation of EO771 cell proliferation by 100 ng/mL IGF-1 when the cells were grown serum-free [38] , and points to FCS as the likely source of stimulatory IGFs. The inhibitory effect of cell-secreted IGFBP-3 is therefore consistent with the sequestration of IGFs in the cell medium by overexpressed IGFBP-3, to inhibit IGF1R activation. The total IGF-1 and IGF-2 concentration in fetal bovine serum has been estimated as 500-900 µg/L [39] ; that is, 5% FCS could contain up to 25-45 ng/mL of total IGFs. Since both IGF1R and IGF1R-insulin receptor hybrids are activated by IGF-1 and IGF-2 with approximately similar potency [40] , this supports the proposal of FCS in medium as a significant source of stimulatory activity. IGFBP-3, which binds IGF-1 and IGF-2 with similar high affinity [41] , would be expected to sequester much of the available IGFs.
Unexpectedly, L24-IGF-1, which is unable to activate IGF1R, also restored normal proliferation in the IGFBP-3-expressing cells. Regardless of the growth-inhibitory mechanism of IGFBP-3 in these cells, the most plausible way in which L24-IGF-1 could stimulate cell growth without itself activating IGF1R signaling is by increasing endogenous IGF bioavailability through the displacement of IGFs bound to local IGFBPs. Therefore the use of this analogue also points to IGF1R-dependent growth inhibition in EO771-BP3 cells compared to EO771-VEC cells.
Compared to control cells, EO771-BP3 cells consistently showed increased total IGF1R levels at the protein but not the mRNA level, indicating that the increase occurred post-transcriptionally and was most likely due to a reversal of receptor downregulation attributable to ambient IGFs. However, the elevated IGF1R levels were not significantly downregulated by added IGF-1 or LR3-IGF-1, as might have been predicted. An alternative reported mechanism by which stabilization of IGF1R at the cell surface can occur is by direct association with IGFBP-rP1, also known as mac25 [42] , although this was not further investigated. Total IGF1R levels have also been shown to be increased in tumor cells at a post-transcriptional level when p53 is overexpressed [43] . As both p53 and IGF1R are substrates for the ubiquitin ligase, Mdm2, the increase in p53 levels was proposed to sequester Mdm2 in the cell nucleus, preventing the targeting of the IGF1R to the proteasome [44] where it is degraded or recycled [45] . EO771 cells show constitutive p53 expression by western blotting, not further inducible by irradiation, consistent with p53 mutation [29] . However, the nature of the mutation, or its effect on Mdm2 binding, is unknown, and is unlikely to differ between EO771-VEC and EO771-BP3 cells. Therefore, an explanation for upregulated IGF1R relating to lower available IGFs in EO771-BP3 cell medium remains most likely.
The growth-inhibitory effect of mammary tumor cell-expressed IGFBP-3, observed in vitro, was not significantly maintained in tumors that successfully established in wild-type and BP3KO mice, as the tumor weights were similar across groups. Considering that the growth of the EO771-BP3 cells was stimulated by IGF-1 in vitro, the loss of growth inhibition in vivo may be attributed to a steady supply of IGF-1 from the mouse circulation. Nonetheless, EO771 cells expressing hIGFBP-3 showed a decreased establishment rate in the BP3KO mice.
BP3KO mice implanted with hIGFBP-3-expressing cells produced low-titer antibodies against IGFBP-3, which were detectable in the serum. In addition, mammary fat pads from the BP3KO mice in which tumors failed to establish showed high levels of T cells. Taken together, these observations suggest that the reduced tumor establishment observed in these mice occurred in conjunction with an immune response against IGFBP-3. 12-to 18-residue peptide fragments of IGFBP-3 have been identified as antigens presented on MHC-II molecules in renal and transitional cell carcinomas [46] , which highlights the possibility of tumor-expressed IGFBP-3 having been presented as an antigen on tumor cells and perceived as a foreign antigen in the BP3KO mice.
It is also possible that BP3KO mice are not immunologically tolerant to the presence of IGFBP-3. Reactive T cells are generated through successive rounds of selection in the primary (thymus) and secondary lymphoid organs [47] . T cells expressing T cell receptor complexes that are compatible with self-antigens are induced to undergo apoptosis or anergy (functionally inactive) in these organs [47] . As the BP3KO mice do not make IGFBP-3 peptides that can be presented as self-antigens, there is a possibility that T cells reactive against IGFBP-3 can be generated when the mouse is exposed to IGFBP-3. This likelihood is increased since the overexpressed IGFBP-3 was of human rather than murine origin, with only 81% sequence similarity.
However, contrary to this interpretation, two previous studies involving the implantation of tumor cells with either endogenous [48] or forced expression [49] of a protein into corresponding knock-out mice, showed no obvious immune reaction against the factor, with primary tumor growth similar between wild-type and knock-out mice (as also seen in our study). In both cases the proteins were transcription factors [38] [39] [40] [41] [42] [43] [44] [45] whereas IGFBP-3 is secreted and therefore liable to antigen presentation through engulfment by macrophages. Notably, the infusion of recombinant Tcf-1, a transcription factor, into Tcf-1-deficient mice [50] resulted in high titer Tcf-1-specific antibodies, suggesting that the generation of an immune response culminating in antibody generation is heightened if the antigen is both present extracellularly and in high amounts. In our case, human IGFBP-3 was undetectable in the serum of mice bearing EO771-BP3 tumors (data not shown). We saw no increased T cell infiltration into the tumors of BP3KO compared to wildtype mice, and only a low titer of circulating antihIGFBP-3 antibodies at the end of the study. However, final tumor weight was inversely related to tumor T cells across all groups. Therefore, although the possibility of heightened antigenicity of hIGFBP-3 compared to mIGFBP-3 cannot be excluded, any immune response appeared confined to the BP3KO mice. We have previously reported an increase in CD3 + cells in EO771 mammary tumors growing in BP3KO compared to wildtype C57BL/6 mice [26] , associated with slower tumor growth in the BP3KO mice, and recently showed that this was potentially attributable to increased tumor CD8 + cytotoxic T cells in the absence of IGFBP-3 in the tumor microenvironment [51] . In that study, tumor Igfbp3 expression (derived solely from the microenvironment in wildtype mice) showed a significant positive correlation with tumor weight [51] , consistent with clinical studies showing high tumor IGFBP-3 as a poor prognostic feature in some breast cancers [7, 9] . This positive growth effect of endogenous IGFBP-3 derived from the tumor microenvironment contrasts with our findings in the present study indicating that IGFBP-3 expression by the mammary carcinoma cells themselves has the potential to inhibit cell proliferation, at least in part through a mechanism that is IGF1R-dependent and reversible by IGF-1.
In vivo, poor tumor growth was associated with marked T cell infiltration in BP3KO mice, although cell subtypes were not investigated.
Conclusions
In summary, this study has shown that the expression of hIGFBP-3 in EO771 cells results in decreased proliferation despite increased IGF1R levels in vitro, and that the growth rate of hIGFBP-3-expressing cells is restored to a similar rate as non-IGFBP-3 expressing cells by exposure to IGF-1 or analogues with reduced affinity for either IGFBP-3 or IGF1R. In tumors implanted into wild-type and BP3KO mice, hIGFBP-3 expression was associated with decreased tumor establishment, but normal growth once established. The contrasting effects of IGFBP-3 expressed by mammary carcinoma cells compared to IGFBP-3 expression by cells in the tumor microenvironment highlight the complexity of growth regulation by IGFBP-3, no doubt contributing to a lack of consensus in the literature as to the prognostic significance of IGFBP-3 in breast and other cancers [1] .
